FOR IMMEDIATE RELEASE. News Abbot and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease ABBOTT PARK, Ill. and IRVING, Texas, September 23, 2010 – Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD). Under the terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets. Reata will receive upfront and near term cash payments of $450 million for the licensing rights to bardoxolone and a minority equity investment in the company. Upon completion of certain development and approval objectives for bardoxolone and other molecules in the licensed territories, Reata will receive additional milestone payments. Reata also will receive royalties on any future product sales in the Abbott territories. Additionally, Abbott obtains rights to develop and commercialize certain other Reata compounds for chronic kidney disease, and for cardiovascular and metabolic indications, in these territories. “Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis,” said Xxxx Xxxxxxx, M.D., senior vice president, pharmaceuticals, research and development, Abbott. “This agreement builds on Xxxxxx’x existing experience in renal care, while adding a promising compound to our later-stage pipeline.” Bardoxolone is an oral, first-in-class antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the kidneys. In two Phase 2 clinical trials, bardoxolone significantly improved kidney function in patients with advanced CKD and Type 2 diabetes. CKD currently affects more than 50 million adults worldwide, and the number of patients is rapidly increasing throughout the world. “Reata is very pleased to have Abbott as our partner and believe that its existing renal capabilities will be a great asset to the global program,” said Xxxxxx Xxxx, chief executive officer of Reata. “This partnership allows us to meet our strategic goal of establishing our own commercial presence in the U.S. and building a sustainable, fully integrated pharmaceutical compan...
FOR IMMEDIATE RELEASE. Media Contacts Baxter Xxxxx Xxxxx, (000) 000-0000 Xxxxxxx Xxxx, (000) 000-0000 Momenta Xxxx Xxxxxx, XxxXxxxxxx Biomedical Communications, (000) 000-0000 Investor Contacts Xxxxxx Xxxx Xxx Xxxxxx, (000) 000-0000 Xxxxx Xxxxxxxxx, (000) 000-0000 Momenta Xxxxxxx Xxxxxx, (000) 000-0000
FOR IMMEDIATE RELEASE. DATE: April 19, 2021 SUBJECT: Atlantic Broadband Cable Television Franchise Agreement
FOR IMMEDIATE RELEASE. Penguin Lands Marine Services Contract in the Middle East Singapore, 4 July 2007 – Penguin Marine Offshore Services Pte. Ltd. ("PMOS"), the ferry chartering and overseas projects arm of Penguin Boat International Ltd. (“Penguin” or “the Group”), has been awarded a marine services contract by the government of Dubai’s Roads and Transport Authority (“RTA”) to manage modern Waterbus operations along Dubai Creek.
FOR IMMEDIATE RELEASE. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators About Reata Pharmaceuticals, Inc.
FOR IMMEDIATE RELEASE. Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
FOR IMMEDIATE RELEASE. Infinity Contacts: Intellikine Contact: About PI3K and INK1197
FOR IMMEDIATE RELEASE. Media Contacts Xxx Xxxxxxxx SVP, Corporate Communications 503.727.4188 xxxxxxxxxxx@xxxxxxxxxx.xxx Xxxx Xxxx VP, Communications and Public Affairs Director 509.626.5348 xxxx.xxxx@xxxxxxxxxxxxxxxx.xxx Investor Contacts Xxx Xxxxxxxxxx EVP/Chief Financial Officer 503.727.4108 xxxxxxxxxxxxx@xxxxxxxxxx.xxx Xxxxxxx X. Xxxxxx EVP/Chief Financial Officer 509.227.0961 xxx.xxxxxx@xxxxxxxxxxxxxxxx.xxx Portland, Ore. and Spokane, Wash. – September 11, 2013 – Umpqua Holdings Corporation (UMPQ) and Sterling Financial Corporation (STSA) announced today that they have entered into a definitive agreement pursuant to which Sterling will merge with and into Umpqua. The transaction will have a total value of approximately $2.0 billion. The merger will result in the West Coast’s largest community bank with expanded geographic reach. The combined organization will have approximately $22 billion in assets, $15 billion in loans and $16 billion in deposits, with 5,000 associates and 394 stores across five states – Oregon, Washington, Idaho, California and Nevada. Umpqua and Sterling have also agreed to establish and fund a $10 million community foundation, underscoring their mutual commitment to serving their communities. Upon completion of the merger, the company will operate under the Umpqua Bank name and brand. It will continue to deliver the high-touch level of service that Umpqua and Sterling customers expect, with an expanded branch and ATM network and a broad range of products and expertise in retail, small business, private and corporate banking; asset and wealth management; and securities brokerage. Sterling Financial Corporation to Merge With Umpqua Holdings Corporation September 11, 2013 Umpqua Holdings Corporation will continue to be led by Xxx Xxxxx as president and CEO. Sterling president and CEO Xxxx Xxxxxx will join Umpqua Bank as co-president, with Umpqua Bank co-president Xxxx X’Xxxxx serving in the same capacity. “Together, Umpqua and Sterling will create something unique in the financial services industry, an organization that offers the products and expertise of a large bank but delivers them with the personal service and commitment of a community bank,” said Xxx Xxxxx. “With our size, shared cultures and financial strength, our combined organization will be uniquely positioned to deliver value for our associates, customers, communities and shareholders. We look forward to starting the process of bringing our companies together.” “Sterling has emerged from its ...
FOR IMMEDIATE RELEASE. Date: May 26, 2020 Contact: Xxxx-Xxxxx Xxxxxx, Vice President, Corporate Communications Phone: (000) 000-0000 e-mail: xxxxxxx@xxxxx.xxx Fax: (000) 000-0000 SOUTH JORDAN, UTAH – Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it has reached an agreement with Starboard Value LP and its affiliates (“Starboard”), an investment firm which owns approximately 8.7% of Merit’s outstanding common stock, pursuant to which the Company has nominated three new independent directors —Xxxxx Xxxxxxxxx, Xxxxx Xxxxx and Xxxxx X. Xxxxx—for election to the Merit Board of Directors at the Company’s upcoming 2020 Annual Meeting of Shareholders, scheduled to be held on June 22, 2020. In connection with the new director nominations, Merit also announced that Xxxxx X. Xxxxxx, Xxxxx X. Xxx, M.D. and Xxxxx X. Xxxx will not stand for re-election at the 2020 Annual Meeting and Xxxxxxxx Xxxxxx, M.D. will resign from the Board not later than immediately following the 2020 Annual Meeting. Merit’s Board intends to appoint Xx. Xxxx to fill the vacancy resulting from Xx. Xxxxxx’x resignation, which would place her in the class of directors standing for re-election at the 2021 Annual Meeting. Xxxx X. Xxxxxxx, a founder of Merit, has previously announced that he will not stand for re-election at the 2020 Annual Meeting. Following the 2020 Annual Meeting, Merit’s Board will be comprised of nine directors, seven of whom will be independent. Merit’s Board intends to select a new Lead Independent Director following the 2020 Annual Meeting.
FOR IMMEDIATE RELEASE. LabCorp Contacts: Xxxxx Xxxxxxx (investors) Xxx Xxx Xxxxx (media) About LabCorp About TACHC
